National Cancer Institute

Phase	Trial	Trial Status	Site Status	Drug	NCT#
2	Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)	Withdrawn	Closed	Selumatinib	NCT03109301
	Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis	Recruiting	Active	Surgery	NCT04557969
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Not yet activated	Linsitinib (OSI-906)	NCT01560260
2	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer	Completed	Closed	Guadecitabine	NCT03165721
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Completed	Active	Rogaratinib	NCT04595747
2	Cabozantinib for Adults With Advanced Soft Tissue Sarcoma	Active, not recruiting	Closed	Cabozantinib	NCT01755195
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862